Search results
Direct Access Colonoscopy Saves Time With Comparable Results
Medscape· 6 days agoDirect access colonoscopy was as effective as office-scheduled colonoscopy for completing screening...
Obesity Special Issue Published in The American Jo | Newswise
Newswise· 4 days agoObesity in gastroenterology is the focus of the June issue of The American Journal of ...
7 Studies Likely to Reshape GI Care in the Years Ahead
Medscape· 2 days agoDr David Johnson highlights the new studies from this year's Digestive Disease Week likely to impact...
Calyx / Invicro Forges a Strategic Collaboration with BAMF Health to Accelerate Clinical Translation...
The Woonsocket Call· 2 days agoCalyx / Invicro, a global leader in providing medical imaging solutions and development services to the clinical research community, today announces a strategic partnership with BAMF Health, ...
In Treating IBD, Consider Diet and Dentistry
Medscape· 4 days agoDr David Johnson highlights five compelling studies from this year's Digestive Disease Week exploring the role of oral health, diet, and intestinal...
Robotic device restores wavelike muscular function involved in processes like digestion
Medical Xpress· 2 days agoA team of Vanderbilt researchers has developed a wirelessly activated device that mimics the wavelike muscular function in the esophagus and small intestine responsible for transporting food and viscous fluids for digestion.
Findings from studies presented at Digestive Disease Week
Medical Xpress· 5 days agoIn one study, Yazan Abboud, M.D., of the Rutgers University New Jersey Medical School in Newark, and...
HEALWELL AI’s Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World...
Digital Journal· 3 days agoHEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, is proud to announce its subsidiary Pentavere Research ...
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with...
Benzinga· 4 days agoNew data from the ELATIVE® Phase III trial show 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeksData from the itch
Outstanding Voices: Dr. Lukejohn Day is working to improve access to health care - San Francisco...
The Business Journals· 3 days agoSeeing his grandmother and great-grandmother struggle to access quality health care inspired Dr. Lukejohn Day to pursue a career in medicine. A member of the Oglala Lakota Nation, raised on ...